Associate Prof in Cancer Genetics @Roswellpark studying drug resistance, metastasis, microenvironment, immunecheckpoints, angiogenesis. See @ebos.bsky.social
Buffalo, NY
Joined September 2014
- Tweets454
- Following919
- Followers580
- Likes359
John Ebos retweeted
Great to see this fun side project from my 3rd year of med school @Jacobs_Med_UB @RoswellPark published in @jitcancer with #JasonMuhitch, #AnuragSingh, @waraonc23, etc, exploring impacts of SBRT on humoral immunity in mRCC:
jitc.bmj.com/content/14/10/e…
1/6
John Ebos retweeted
Why is kidney cancer advocacy stronger when patients, clinicians, and researchers speak together?
Dr. Jason Muhitch shares his perspective on the power of bringing these voices together in meetings with Congress and discusses the research from #KCRS26 that he believes has the greatest potential to change patient care.
Watch the full conversation to hear his perspective on advocacy, collaboration, and the future of kidney cancer research.
#AcceleratingCures
John Ebos retweeted
Phase III BR.31 results @JCO_ASCO - adjuvant durvalumab for resected NSCLC: no difference in DFS in the primary population PD-L1 ≥ 25% (HR 0.93) or any of the secondary populations. More inconsistency in the adjuvant setting in contrast to neoadjuvant.
ascopubs.org/doi/10.1200/JCO…
John Ebos retweeted
Want to know what we do at Inria - Inserm COMPO ?
Have a look at this blog post where I explain success stories of hashtag#mechanistic hashtag#learning to improve clinical oncology.
mathematical-oncology.org/bl…
John Ebos retweeted
This work was the result of years of dedicated work and sacrifice by Yuhao (Tom) Shi @tshi42, a talented @UBuffaloMDPhDstudent in the @EbosLab who received F30 @NIHFunding from @NCICancerBio and is now doing his residency at NYU @NYULH_RadOnc. Congratulations Tom!
John Ebos retweeted
We found that the interferon-regulated secretory machinery in tumor cells is ‘rewired’ after acquired resistance to PD-L1 inhibition, altering the immune microenvironment and decreasing the tumor-killing ability of T cells. @RoswellPark #MedTwitter #Oncology #ImmunoOnc
John Ebos retweeted
Thrilled to share our story out in Cancer Cell, led by the amazing Kay Hanggi (now on the job market). We show that necrotic forms of cell death and the subsequent release of IL1a drives myeloid-based immune suppression in models of breast cancer. (1/11)
cell.com/cancer-cell/abstrac…
John Ebos retweeted
Senescence as a therapeutic target in cancer and age-related diseases nature.com/articles/s41573-0…
This new review evaluates the status of senotherapies, including senolytics, senomorphics, interventions that mitigate senescence and strategies that harness the immune system
John Ebos retweeted
#ICYMI: Neoadjuvant immune checkpoint inhibitors improve outcomes for early-stage #TNBC and PD-L1+ tumors. #BreastCancer #BCSM oncnursingnews.com/view/neoa…
John Ebos retweeted
Excited for this @UBuffalo collaboration with @NYSOPWDD to characterize a novel treatment strategy for Alzheimer's Disease.
A professor from @UBuffalo is reshaping the treatment of Alzheimer's🙌. Alongside a team of researchers across NY, Jonathan Lovell, PhD, is developing an immunotherapy approach that could reverse the disease's progression.
Learn more: buffalo.edu/news/releases/20…
ALT A photorealistic image depicting the two main disease hallmarks of Alzheimer's disease. which destroy neuronal networks, are amyloid plaques and neurofibrillary tangles.
John Ebos retweeted
Paper out in final form
sciencedirect.com/science/ar…
@MustangNatalie did a great job driving it.
@jbiolchem is a great home for it. $2300 with the @ASBMB member discount - great value. Submission/review/Publication process was fair and quick. BTW that is a lung met lit up by the BB
John Ebos retweeted
RNAseq is commonly performed. We compared N=30 wild-type Bl6 mice to an N=30 heterozygotic knockout with a phenotype, and then downsized. We found you need at least an N= 8-12 to avoid a >50% false positive rate. A 2nd line confirmed the finding.
biorxiv.org/content/10.1101/…
John Ebos retweeted
Summary of our paper scim.ag/7p1 on combining JAK inhibitors with anti-PD1 for lung cancer (NSCLC). Part of a bench-to-bedside journey to understand opposing roles of IFN in IO. Wonderful team w @EJohnWherry @divijmathew Caitlin Foley @MMarmarelis @Jbauml et al! 1/13
John Ebos retweeted
New #JITC position article and guidelines: Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision bit.ly/4evIXAp
@EmensLeisha @AnaAndersonlab @BcellBruno @CapitiniMD @deborahcollyar @gulleyj1 @PatrickHwuMD @IAmDrDex @annwsilkmd @JenWargoMD
John Ebos retweeted
Pleased to share our latest work in wound healing mechanics orchestrated by YAP/TAZ and Agrin @theJIDJournal Congratulations to all authors for their hard work 🙏 @WanjinH @RoswellPark
jidonline.org/article/S0022-…
John Ebos retweeted
A Review in @NatureMedicine outlines the state of the art of artificial intelligence in the preoperative, intraoperative and postoperative settings, where it has enormous potential to improve patient outcomes, surgical education and system efficiencies. 🔒 go.nature.com/4bk6ouA
ALT This is figure 1, which shows the integration of novel AI-powered digital interventions in the intraoperative setting.
John Ebos retweeted
Extremely happy to share our latest paper with @EbosLab @RoswellPark in @PLOSCompBiol : Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment.
#mechanisticLearning
journals.plos.org/ploscompbi…
John Ebos retweeted
Adjuvant pembrolizumab shows a significant and clinically meaningful OS benefit in intermediate and high risk clear cell renal cancer for the 1st time (KN564). This further tips the balance towards giving adjuvant pembro in this setting @NEJM @DrChoueiri nejm.org/doi/full/10.1056/NE…
John Ebos retweeted
New #JITC article: Impact of immunotherapy time-of-day infusion on survival & immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis bit.ly/3IVUE4P @careyjans @bilenma @MohammadKhanMD @HaydnKissick @zach_buchwald @dave_qian
John Ebos retweeted
Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms dlvr.it/T41JfX
